Co-Authors
This is a "connection" page, showing publications co-authored by DIMPY KOUL and SIYUAN ZHENG.
Connection Strength
1.172
-
Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. Nat Commun. 2021 01 08; 12(1):139.
Score: 0.195
-
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 03 15; 26(6):1395-1407.
Score: 0.182
-
Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 10 01; 79(19):5088-5101.
Score: 0.177
-
Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):78-91.
Score: 0.159
-
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget. 2017 Mar 28; 8(13):21741-21753.
Score: 0.150
-
A high Notch pathway activation predicts response to ? secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells. 2014 Jan; 32(1):301-12.
Score: 0.120
-
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev. 2013 Jul 01; 27(13):1462-72.
Score: 0.116
-
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. Oncotarget. 2017 Aug 15; 8(33):54285-54296.
Score: 0.038
-
MSK1-Mediated ?-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Mol Cancer Ther. 2016 07; 15(7):1656-68.
Score: 0.035